Actinium Pharmaceuticals (ATNM) Trading Up 4.1%

Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) shares were up 4.1% during trading on Tuesday . The stock traded as high as $0.77 and last traded at $0.76. Approximately 1,230,300 shares traded hands during mid-day trading, an increase of 8% from the average daily volume of 1,142,880 shares. The stock had previously closed at $0.73.

ATNM has been the subject of several analyst reports. Maxim Group reissued a “buy” rating on shares of Actinium Pharmaceuticals in a report on Thursday, June 14th. B. Riley set a $3.00 price target on shares of Actinium Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 15th. Finally, Zacks Investment Research raised shares of Actinium Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a report on Tuesday, July 24th. Five investment analysts have rated the stock with a buy rating, Actinium Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $3.75.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last released its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02.

Several institutional investors and hedge funds have recently made changes to their positions in ATNM. Sabby Management LLC bought a new stake in Actinium Pharmaceuticals during the first quarter worth about $729,000. Anson Funds Management LP bought a new stake in Actinium Pharmaceuticals during the first quarter worth about $1,502,000. Sio Capital Management LLC bought a new stake in Actinium Pharmaceuticals during the first quarter worth about $393,000. Worth Venture Partners LLC bought a new stake in Actinium Pharmaceuticals during the first quarter worth about $140,000. Finally, Renaissance Technologies LLC boosted its stake in Actinium Pharmaceuticals by 1,269.5% during the second quarter. Renaissance Technologies LLC now owns 387,500 shares of the biotechnology company’s stock worth $248,000 after acquiring an additional 359,205 shares in the last quarter.

Actinium Pharmaceuticals Company Profile (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.

See Also: Exchange-Traded Funds (ETFs)

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply